Nippon Kayaku Kabushiki Kaisha

Yukihiro Nishiyama

Seiichi Saito

Nobuyoshi Shimada

Hiroo Hoshino

Takemitsu Nagahata

Kenichi Matsubara

Katsutoshi Takahashi

Shigeru Hasegawa

Jun-ichi Seki

Masayuki Kitagawa

Akio Fujii

Akira Masuda

Hideo Sugimura

Akira Shiozawa

Kazuhisa Narita

Yuh-ichiro Ichikawa

Takayuki Tomizawa

Kouwa Yamashita

Yuka Sugawara

Hiroshi Akaba

Kyoichi Shibuya

Sayuri Kato

This invention relates to cyclobutane derivatives represented by the following general formula (1) and physiologically acceptable salts thereof: ##STR1## wherein B represents a nucleic acid base derivative, R.sup.1 and R.sup.2 independently represent hydrogen atom, dialkylaminoacyl group, 1,4-dihydro-1-methylnicotinoyl group or substituted phosphoric acid group, provided that either one of R.sup.1 and R.sup.2 is a group other than hydrogen atom. The compounds of this invention exhibit a high oral absorbability and are metabolized in vivo into the compounds of formula (1a). Accordingly, the compounds of this invention are expectedly useful as antiviral agent.

Phenoxyphosphoryloxymethyl cyclobutyl purines

It was found that 2-halogeno-oxetanocin A and 4'-phosphate thereof represented by the following general formula (1): ##STR1## wherein X represents a halogen atom and R represents a hydrogen atom or a phosphoric acid residue ##STR2## or salts thereof exhibit a strong antiviral activity and are useful as an active ingredient of therapeutic drug for viral diseases. Further, it was also found that the compounds of this invention are characterized in that they are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity.

2-halogeno-oxetanocin A and phosphoric ester thereof

This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities.

Oxetanocins

The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represents a purine base residue, and pharmacologically acceptable salts thereof.

Antiviral phosphoric acid esters of oxetanocins

This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),

Oxetanocin-related compounds and pharmaceutical compositions containing

Growing community of inventors

Aichi, Japan

Yukihiro Nishiyama